Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial-Reference-Cited by-同舟云学术

Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial

Published:2022-01 Issue:1 Volume:16 Page:102382
ISSN:1871-4021
Container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews
language:en
Short-container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews

Author:

Lee Matthew M.Y.,Kristensen Søren L.,Gerstein Hertzel C.,McMurray John J.V.,Sattar Naveed^ORCID

Publisher

Elsevier BV

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference4 articles.

1. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials;Sattar;Lancet Diabetes Endocrinol,2021

2. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial;Ruff;Nat Med,2021

3. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes;Holman;N Engl J Med,2017

4. Proposal to refuse to approve a new drug application for ITCA 650 (exenatide in DUROS device); opportunity for a hearing;Fed Regist,2021

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efectos cardiometabólicos de la pérdida de peso;Atención Primaria;2024-10

2. Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence;Current Pharmaceutical Design;2024-08

3. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies;Cardiovascular Diabetology;2024-03-18

4. Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial;European Heart Journal - Cardiovascular Pharmacotherapy;2024-01-25

5. Discovery of non-peptide GLP-1r natural agonists for enhancing coronary safety in type 2 diabetes patients;Journal of Biomolecular Structure and Dynamics;2024-01-02